What is FULC's current stock price?

As of now, FULC is trading at $12.80, with a daily change of -7.25%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

FULC Stock Analysis & IQ Rating | Fulcrum Therapeutics

FULC

Fulcrum Therapeutics

$12.80

-$1.00 | -7.25%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$15.74

MKT CAP

$692.72M

52W Low

$2.32

VOL

$3.00M

P/E Ratio

N/A

AVG VOL

$1.91M

RSI

61.17

TREND

Uptrend

FULC Stock IQ

Login to see Fulcrum Therapeutics (FULC) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

FULC Target Price

Login to display

Strengths

FULC Rewards

Earnings are forecast to grow

FULC Rewards

Trading below its fair value

Technical Indicators

FULC Technical Indicators

Overbought

FULC Price Performance

$8.65 (+47.98%)

$7.54 (+69.76%)

$7.91 (+61.82%)

$4.84 (+164.46%)

1year

6month

3month

1month

FULC Risk Level

FULC has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

High volatilty

Extreme

LOW

HIGH

FULC Analysts Opinion

FULC overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

FULC Analysts Opinion

FULC Analysts opinion is negative and it remained unchanged from the past 3 months

FULC Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

94%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

FULC Street Sentiment

FULC Street Sentiment is extremely bullish and have positive views on the near-term outlook

FULC Performance Sentiment

Sentiments overview associated with FULC events and the stock performance.

94%

0%

Positive

Negative

15 out of 16
events present

0 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$12.99

Resistance
Price

$7.67

Current Price Range

$14.11

Show methods +

Linked to FULC

IQ

Close Price

Change

SNY

4.02

48.86

+1.24%

PFE

3.94

25.80

+0.08%

NVO

3.91

50.29

+2.49%

FULC Latest Analysis +

Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation. Fintel reports that on December 11 2025 Truist Securities maintained coverage of Fulcrum Therapeutics (NasdaqGM:FULC) with a Buy recommendation. Analyst Price Forecast Suggests 14.26% Upside

Today

$13.00 | +1.56%

Rating

Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock pre-funded warrants.

Wed Dec 10, 2025

$13.80 | -5.48%

Activity

Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock.

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results. ) stock is surging on Monday after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir .“.We are highly encouraged by these initial data from the 20 mg cohort which show clear evidence of a dose-response and build on the strong profile established with the 12 mg cohort”. said Alex Sapir Fulcrum’.s President and CEO.Mean absolute fetal hemoglobin

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Momentum

Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results.

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). CAMBRIDGE Mass. Dec. 05 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics Inc.® (Nasdaq: FULC) a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the companys common stock pur

Fri Dec 5, 2025

$8.90 | +1.60%

Activity

Potential

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies | DelveInsight. Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies |. DelveInsightThe sickle cell disease marke

Wed Dec 3, 2025

$9.06 | +1.23%

Activity

Potential

Fulcrum To Present New PIONEER Trial Data In Sickle Cell Disease . (RTTNews) - Fulcrum Therapeutics Inc. (FULC) will present new clinical data from its PIONEER trial in an investor event on December 7 2025 at 7:00 a.m. ET.

Wed Dec 3, 2025

$9.06 | +1.23%

Activity

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7 2025. CAMBRIDGE Mass. Dec. 02 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics Inc.®. (NASDAQ:) a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases will host an investor event on Sunday December 7 2025 at 7:00 a.m. ET to review new clinical data from th

Tue Dec 2, 2025

$8.95 | -9.32%

Activity

FAQ About FULC Stock Insights

What is FULC current stock price?

What are FULC stock strengths?

What is FULC Risk Level?

What is FULC market cap and volume?

What is FULC current Stock IQ?

Should I buy FULC stock right now?

Is FULC a Strong Buy right now?

What does a 'Strong Buy' rating mean for FULC?

What does a 'Strong Sell' rating mean for FULC?

What factors influence FULC's Stock IQ?

Explore our FULC Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored FULC Stock Strategies
Effective Risk Management

FIND US ON

Receive our FULC Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

FULC

Fulcrum Therapeutics

Current Price

$12.80

-$1.00 | -7.25%

52W High

$15.74

MKT CAP

$692.72M

52W Low

$2.32

VOL

$3.00M

P/E Ratio

N/A

AVG VOL

$1.91M

RSI

61.17

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

FULC Rewards

Earnings are forecast to grow

FULC Rewards

Trading below its fair value

Technical Indicators

FULC Technical Indicators

Overbought

Linked to FULC

Symbol

IQ

Close

Change

SNY

4.02

48.86

+1.24%

PFE

3.94

25.80

+0.08%

NVO

3.91

50.29

+2.49%

FULC Price Performance

$8.65 (+47.98%)

$7.54 (+69.76%)

$7.91 (+61.82%)

$4.84 (+164.46%)

1year

6month

3month

1month

FULC Analysts Opinion

FULC Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

FULC Analysts Opinion

FULC Analysts opinion is negative and it remained unchanged from the past 3 months

FULC Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

94%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

FULC Street Sentiment

FULC Street Sentiment is extremely bullish and have positive views on the near-term outlook

FULC Risk Level

FULC has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

High volatilty

Extreme

LOW

HIGH

FULC Performance Sentiment

Sentiments overview associated with FULC events and the stock performance.

94%

0%

Positive

Negative

15 out of 16
events present

0 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$12.99

Resistance
Price

$7.67

Current Price Range

$14.11

Show methods +

FULC Stock IQ

Login to unlock Fulcrum Therapeutics (FULC) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

FULC Latest Analysis

Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation. Fintel reports that on December 11 2025 Truist Securities maintained coverage of Fulcrum Therapeutics (NasdaqGM:FULC) with a Buy recommendation. Analyst Price Forecast Suggests 14.26% Upside

Today

$13.00 | +1.56%

Rating

Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock pre-funded warrants.

Wed Dec 10, 2025

$13.80 | -5.48%

Activity

Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock.

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results. ) stock is surging on Monday after the company released initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir .“.We are highly encouraged by these initial data from the 20 mg cohort which show clear evidence of a dose-response and build on the strong profile established with the 12 mg cohort”. said Alex Sapir Fulcrum’.s President and CEO.Mean absolute fetal hemoglobin

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Momentum

Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results.

Mon Dec 8, 2025

$12.99 | +45.96%

Activity

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). CAMBRIDGE Mass. Dec. 05 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics Inc.® (Nasdaq: FULC) a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the companys common stock pur

Fri Dec 5, 2025

$8.90 | +1.60%

Activity

Potential

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies | DelveInsight. Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies |. DelveInsightThe sickle cell disease marke

Wed Dec 3, 2025

$9.06 | +1.23%

Activity

Potential

Fulcrum To Present New PIONEER Trial Data In Sickle Cell Disease . (RTTNews) - Fulcrum Therapeutics Inc. (FULC) will present new clinical data from its PIONEER trial in an investor event on December 7 2025 at 7:00 a.m. ET.

Wed Dec 3, 2025

$9.06 | +1.23%

Activity

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7 2025. CAMBRIDGE Mass. Dec. 02 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics Inc.®. (NASDAQ:) a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases will host an investor event on Sunday December 7 2025 at 7:00 a.m. ET to review new clinical data from th

Tue Dec 2, 2025

$8.95 | -9.32%

Activity

Discover FULC Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of FULC. We're here to help you make informed investment decisions today.

FIND US ON

Receive our FULC Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

FULC Stock trends

FULC Stock performance

FULC Stock analysis

FULC investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing FULC

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing FULC

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

FULC Stock Analysis & IQ Rating | Fulcrum Therapeutics

FULC Stock IQ

FULC Target Price

FULC Risk Level

FULC Analysts Opinion

FULC Street Sentiment

FULC Performance Sentiment

Technical Price Levels

Explore our FULC Stock insights

Receive our FULC Daily Alerts

FULC Street Sentiment

FULC Risk Level

Technical Price Levels

Discover FULC Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of FULC. We're here to help you make informed investment decisions today.

Receive our FULC Daily Alerts

FULC Runner Alarm